Related Experiment Video
Updated: May 15, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Lung function and nonalcoholic fatty liver disease: a Mendelian randomization study
Jiran Shen1, Yue Wang2, Sijing Zhou3
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Reduced lung function, specifically forced expiratory volume in 1 second (FEV1), is causally linked to a higher risk of non-alcoholic fatty liver disease (NAFLD). This finding suggests FEV1 may aid in NAFLD risk assessment and prevention strategies.
Area of Science:
- Pulmonology
- Hepatology
- Genetics
Background:
- Observational studies suggest links between pulmonary function (FEV1, FVC) and non-alcoholic fatty liver disease (NAFLD).
- Observational data are limited by bias and reverse causality, hindering causal inference.
Purpose of the Study:
- To investigate the causal effect of pulmonary function on NAFLD risk.
- To employ Mendelian randomization (MR) to establish causality.
Main Methods:
- Univariate, multivariate, and bidirectional two-sample MR analyses were conducted.
- Inverse variance weighting was the primary analysis method, supplemented by complementary methods.
- Sensitivity analyses were performed to assess pleiotropy.
Main Results:
- Increased FEV1 and FVC showed associations with decreased NAFLD risk.
- After adjusting for height, only FEV1 maintained a significant association with reduced NAFLD risk.
- No significant causal effect of NAFLD on lung function was detected in reverse MR analysis.
Conclusions:
- Reduced lung function, particularly FEV1, is causally associated with increased NAFLD risk.
- FEV1 may serve as a valuable marker for NAFLD risk assessment.
- Targeting FEV1 could be a potential strategy for NAFLD prevention.
More Related Videos
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024